4,504 results
Search Results
52. Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the 'gluten' from 'non‐coeliac gluten sensitivity'. Authors' reply.
53. Letter: hepatitis B virus infection and risk of multiple myeloma—a meta‐analysis of cohort studies. Authors' reply.
54. Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding.
55. Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID‐19 in the United Kingdom.
56. Letter: risk of severe COVID‐19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPARE‐IBD multicentre cohort study.
57. Editorial: moving from the clinic towards population hepatology—authorsʼ reply.
58. Letter: enhancing training opportunities for upper GI bleeding in Sheffield—a UK transferable model?
59. Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems.
60. Letter: non‐invasive transabdominal stimulation device for the treatment of chronic constipation—proof‐of‐principle study in adults.
61. Letter: inflammatory bowel disease services during the Covid‐19 pandemic ‐ authors' reply.
62. Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply.
63. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply.
64. Editorial: Crystalising the burden of steatotic liver disease—Authors' reply.
65. Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
66. Editorial: Crystalising the burden of steatotic liver disease.
67. Letter: Bif195 for aspirin‐induced gastric mucosal damage—More to do in further research.
68. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.
69. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find.
70. Editorial: Adequate protein intake is more crucial than the profile of amino acids intake for sarcopenia prevention during the earlier stages of liver cirrhosis.
71. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
72. Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis?
73. Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
74. Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis.
75. Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
76. Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply.
77. Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management.
78. Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D—Authors' reply.
79. Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go... Authors' reply'.
80. Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms–still a long way to go...
81. Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
82. Editorial: Recompensation in PBC is good. But is it good enough?
83. Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies.
84. Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection.
85. Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D.
86. Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply.
87. Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.
88. Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B.
89. Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
90. Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
91. Editorial: Muscles at the expense of liver injury. Is it worth it?
92. Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply.
93. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.
94. Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease—authors' reply.
95. Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?
96. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply.
97. Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world.
98. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.
99. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight.
100. Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding—the promise, controversies and future directions. Author's reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.